Evidence map›Paper›PMID 26888480›Full record

ArticleBiotechnology and bioengineering2016

A reductionist metastasis-on-a-chip platform for in vitro tumor progression modeling and drug screening.

Aleksander Skardal, Mahesh Devarasetty, Steven Forsythe, Anthony Atala, Shay Soker

Open access · greenAbstract read
In one paragraph

Article in Biotechnology and bioengineering, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 1 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 1 synthesis or guideline pooled it, 222 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Frontiers in immunology · 2026
    Review
  4. Cancer metastasisFrontiers in bioengineering and biotechnology · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Targeted Cancer Therapy-on-A-Chip.Advanced healthcare materials · 2024
    Review
  15. Article
  16. Review
  17. Advancements in 3D In Vitro Models for Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  18. Review
  19. Review
  20. Review

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Aleksander SkardalWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina. askardal@wakehealth.edu.
Mahesh DevarasettyWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina.
Steven ForsytheWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina.
Anthony AtalaWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina.
Shay SokerWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina.
Forest Institute · USAtrium Health Wake Forest Baptist · USWake Forest University · US

Funding

(PQB6)An Integrative Computational and Bioengineered Tissue Model of MetastasisR01CA180149 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI AGUS, DAVID B, ATALA, ANTHONY · 2013 to 2016
$2.3M
Studies in Translational Regenerative MedicineT32EB014836 · NIBIB · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ANTHONY ATALA, Victoria Weis · 2013 to 2026
$1.7M
NCI NIH HHS R01 CA180149NIBIB NIH HHS T32 EB014836
6 · The paper itself

Abstract

Current animal and 2-D cell culture models employed in metastasis research and drug discovery remain poor mimics of human cancer physiology. Here we describe a "metastasis-on-a-chip" system allowing real time tracking of fluorescent colon cancer cells migrating from hydrogel-fabricated gut constructs to downstream liver constructs within a circulatory fluidic device system that responds to environmental manipulation and drug treatment. Devices consist of two chambers in which gut and liver constructs are housed independently, but are connected in series via circulating fluid flow. Constructs were biofabricated with a hyaluronic acid-based hydrogel system, capable of a variety of customizations, inside of which representative host tissue cells were suspended and metastatic colon carcinoma tumor foci were created. The host tissue of the constructs expressed normal epithelial markers, which the tumor foci failed to express. Instead, tumor regions lost membrane-bound adhesion markers, and expressed mesenchymal and proliferative markers, suggesting a metastatic phenotype. Metastatic tumor foci grew in size, eventually disseminating from the intestine construct and entering circulation, subsequently reaching in the liver construct, thus mimicking some of the migratory events observed during metastasis. Lastly, we demonstrated the ability to manipulate the system, including chemically modulating the hydrogel system mechanical properties and administering chemotherapeutic agents, and evaluated the effects of these parameters on invasive tumor migration. These results describe the capability of this early stage metastasis-on-a-chip system to model several important characteristics of human metastasis, thereby demonstrating the potential of the platform for making meaningful advances in cancer investigation and drug discovery. Biotechnol. Bioeng. 2016;113: 2020-2032. © 2016 Wiley Periodicals, Inc.

Indexed as

Models, BiologicalAnimalsCell Line, TumorDrug Evaluation, PreclinicalHCT116 CellsHep G2 CellsHumansHydrogelsMiceMicrofluidic Analytical TechniquesNeoplasm MetastasisNeoplasmsTissue Array AnalysisHydrogelscancerdiagnosticshydrogelin vitro modelsorgans-on-a-chip

Identifiers

PMID26888480
PMCPMC5778914
OpenAlexW2283306732

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.